NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Argos Therapeutics, Inc. (Formerly Merix Bioscience) 

4233 Technology Drive

Durham  North Carolina  27704  U.S.A.
Phone: 919-287-6300 Fax: 919-287-6301


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology


Collaborations

Duke University  Exclusive license to the RNA based vaccine technology.

Rockefeller University  Exclusive worldwide rights to technology developed at Rockefeller relating to generation of dendritic cells.

Baylor University  Clinical and preclinical research in Lupus.

Kirin Brewery Co., Ltd.  The companies will collaborate to develop and commercialize dendritic cell vaccines, initially in the areas of cancer and infectious diseases.

Erlangen University  Clinical and preclinical research in Melanoma.





 Company News
Argos Therapeutics, Inc. Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference 10/21/2009 8:44:15 AM    More...
Argos Therapeutics, Inc. to Present Positive Immune Response and Viral Load Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference 10/13/2009 8:36:06 AM    More...
Argos Therapeutics, Inc. Publishes Research on the Immunosuppressive Properties of HIV 6/10/2009 8:52:31 AM    More...
Argos Therapeutics, Inc. Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the American Transplant Congress 6/1/2009 11:28:04 AM    More...
Argos Therapeutics, Inc. Announces Participation at BIO 2009 International Convention 5/13/2009 9:08:32 AM    More...
Argos Therapeutics, Inc. Presents Research Validating Feasibility and Safety of its Arcelis(TM) Personalized Immunotherapy Platform for HIV 4/24/2009 9:20:21 AM    More...
Argos Therapeutics, Inc. Presents Research on the Development and Evaluation of Immunotherapies for HIV 3/24/2009 9:02:22 AM    More...
Argos Therapeutics, Inc. Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the Canadian Society of Transplantation Congress 3/6/2009 10:36:59 AM    More...
Argos Therapeutics, Inc. Completes $35.2 Million Series C Financing 11/21/2008 10:42:16 AM    More...
Argos Therapeutics, Inc. to Discuss Personalized Dendritic Cell Immunotherapy Process at iSBTc Annual Meeting 10/31/2008 8:40:47 AM    More...
123456